Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro

Fig. 4

Control-normalized changes in the expression and phosphorylation of PI3K and MAPK signalling proteins induced by 0.1 μM concentration at two different time points of the PI3K inhibitors a pictilisib at 30 min and 6 h, b apitolisib at 30 min and 6 h, c cobimetinib at 30 min and 6 h, d the combination of pictilisib with cobimetinib at 30 min and 6 h, and e the combination of apitolisib with cobimetinib at 30 min and 6 h. The specific phosphorylation sites evaluated are indicated (e.g. AKT (T308) in AKT phosphorylation at threonine 308). Cell lines displaying significant differential changes (P < 0.05) in protein expression and phosphorylation are shown in boxes

Back to article page